Introduction The novel coronavirus disease 2019 (COVID-19) has rapidly spread across the globe, overwhelming healthcare systems and depleting resources. The infection has a wide spectrum of presentations, and pre-existing comorbidities have been found to have a dramatic effect on the disease course and prognosis. We sought to analyze the effect of asthma on the disease progression and outcomes of COVID-19 patients. Methods We conducted a multi-center retrospective study of positively confirmed COVID-19 patients from multiple hospitals in Louisiana. Demographics, medical history, comorbidities, clinical presentation, daily laboratory values, complications, and outcomes data were collected and analyzed. The primary outcome of interest was in-hospital mortality. Secondary outcomes were Intensive Care Unit (ICU) admission, risk of intubation, duration of mechanical ventilation, and length of hospital stay. Results A total of 502 COVID-19 patients (72 asthma and 430 non-asthma cohorts) were included in the study. The frequency of asthma in hospitalized cohorts was 14.3%, higher than the national prevalence of asthma (7.7%). Univariate analysis revealed that asthma patients were more likely to be obese (75% vs 54.2%, p=0.001), with higher frequency of intubation (40.3% vs 27.8%, p = 0.036), and required longer duration of hospitalization (15.1±12.5 vs 11.5±10.6, p=0.015). After adjustment, multivariable analysis showed that asthmatic patients were not associated with higher risk of ICU admission (OR=1.81, 95%CI=0.98-3.09, p=0.06), endotracheal intubation (OR=1.77, 95%CI=0.99-3.04, p=0.06) or complications (OR=1.37, 95%CI=0.82-2.31, p=0.23). Asthmatic patients were not associated with higher odds of prolonged hospital length of stay (OR=1.48, 95%CI=0.82-2.66, p=0.20) or with the duration of ICU stay (OR=0.76, 95%CI=0.28-2.02, p=0.58). Kaplan-Meier curve showed no significant difference in overall survival of the two groups (p=0.65). Conclusion Despite the increased prevalence of hospitalization in asthmatic COVID-19 patients compared to the general population, after adjustment for other variables, it was neither associated with increased severity nor worse outcomes.

中文翻译：

---

COVID-19中的哮喘：脖子上有多余的链条吗？

简介新型冠状病毒病2019（COVID-19）已在全球迅速传播，医疗系统不堪重负，资源枯竭。感染具有广泛的表现形式，并且已经存在的合并症对疾病进程和预后具有显着影响。我们试图分析哮喘对COVID-19患者疾病进展和预后的影响。方法我们对路易斯安那州多家医院的经确诊的COVID-19患者进行了多中心回顾性研究。收集并分析人口统计学，病史，合并症，临床表现，每日实验室值，并发症和结局数据。感兴趣的主要结果是院内死亡率。次要结果是重症监护病房（ICU）入院，插管风险，机械通气的持续时间和住院时间。结果本研究共纳入502例COVID-19患者（72例哮喘和430例非哮喘患者）。住院队列中哮喘的发生率为14.3％，高于全国哮喘患病率（7.7％）。单因素分析表明，哮喘患者更容易肥胖（75％vs 54.2％，p = 0.001），插管频率更高（40.3％vs 27.8％，p = 0.036），并且需要更长的住院时间（15.1± 12.5比11.5±10.6，p = 0.015）。调整后，多变量分析显示哮喘患者与ICU入院（OR = 1.81，95％CI = 0.98-3.09，p = 0.06），气管插管（OR = 1.77，95％CI = 0.99-3.04）的较高风险无关。 ，p = 0.06）或并发症（OR = 1.37，95％CI = 0.82-2.31，p = 0.23）。哮喘患者与住院时间延长的可能性较高（OR = 1.48，95％CI = 0.82-2.66，p = 0.20）或ICU住院时间无关（OR = 0.76，95％CI = 0.28-2.02） ，p = 0.58）。Kaplan-Meier曲线显示两组的总生存期无显着差异（p = 0.65）。结论尽管与普通人群相比，哮喘COVID-19患者的住院患病率有所增加，但在调整其他变量后，这与严重程度的提高或预后的恶化无关。